Analysts’ Weekly Ratings Changes for Vera Therapeutics (VERA)

Several brokerages have updated their recommendations and price targets on shares of Vera Therapeutics (NASDAQ: VERA) in the last few weeks:

• 8/17/2026 – Vera Therapeutics had its “neutral” rating reaffirmed by Wedbush. They now have a $34.00 price target on the stock.
• 8/12/2026 – Vera Therapeutics had its price target lowered by HC Wainwright from $125.00 to $90.00. They now have a “buy” rating on the stock.
• 8/11/2026 – Vera Therapeutics had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $84.00 price target on the stock.
• 8/11/2026 – Vera Therapeutics had its price target lowered by Wedbush from $43.00 to $34.00. They now have a “neutral” rating on the stock.
• 7/17/2026 – Vera Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/8/2026 – Vera Therapeutics had its price target raised by TD Cowen from $73.00 to $78.00. They now have a “buy” rating on the stock.
• 7/8/2026 – Vera Therapeutics had its price target raised by Guggenheim from $56.00 to $76.00. They now have a “buy” rating on the stock.
• 7/8/2026 – Vera Therapeutics was given a new $125.00 price target by Needham & Company LLC.
• 7/8/2026 – Vera Therapeutics had its price target raised by Wedbush from $35.00 to $43.00. They now have a “neutral” rating on the stock.
• 7/8/2026 – Vera Therapeutics had its price target raised by HC Wainwright from $110.00 to $125.00. They now have a “buy” rating on the stock.
• 7/7/2026 – Vera Therapeutics had its price target raised by Bank of America Corporation from $65.00 to $70.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In other Vera Therapeutics news, CEO Marshall Fordyce sold 46,250 shares of the business’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the completion of the transaction, the chief executive officer owned 151,994 shares in the company, valued at approximately $6,429,346.20. The trade was a 23.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is currently owned by corporate insiders.

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.